Tissue engineered vascular grafts: Origins, development, and current strategies for clinical application

Benrashid, Ehsan; McCoy, C. Cameron; Youngwirth, Linda M.; Kim, Jina; Manson, Roberto J.; Otto, James C.; Lawson, Jeffrey H.

doi:10.1016/j.ymeth.2015.07.014

Cited by 81 publications

(47 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Biomimetic nanofiber vascular grafts (Ong et al, ) are emerging as novel vascular conduits that have the potential to avoid the shortcomings of other graft materials through attributes such as low incidence of infections, long‐term patency, antithrombotic luminal surfaces, functional remodeling capacity, and durability (Benrashid et al, ). The nanofiber scaffolds biodegrade over time, allowing the formation of vascular neotissue, thereby creating a vascular tissue construct that has growth potential (Brennan et al, ).…”

Section: Introductionmentioning

confidence: 99%

“…The nanofiber scaffolds biodegrade over time, allowing the formation of vascular neotissue, thereby creating a vascular tissue construct that has growth potential (Brennan et al, ). The resultant neovessel can be completely integrated with the native vascular system through remodeling, thus reducing the need for reoperation, a significant complication of conventional graft materials (Benrashid et al, ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Different degradation rates of nanofiber vascular grafts in small and large animal models

Fukunishi

Ong

Yesantharao

et al. 2020

J Tissue Eng Regen Med

View full text Add to dashboard Cite

Nanofiber vascular grafts have been shown to create neovessels made of autologous tissue, by in vivo scaffold biodegradation over time. However, many studies on graft materials and biodegradation have been conducted in vitro or in small animal models, instead of large animal models, which demonstrate different degradation profiles. In this study, we compared the degradation profiles of nanofiber vascular grafts in a rat model and a sheep model, while controlling for the type of graft material, the duration of implantation, fabrication method, type of circulation (arterial/venous), and type of surgery (interposition graft). We found that there was significantly less remaining scaffold (i.e., faster degradation) in nanofiber vascular grafts implanted in the sheep model compared with the rat model, in both the arterial and the venous circulations, at 6 months postimplantation. In addition, there was more extracellular matrix deposition, more elastin formation, more mature collagen, and no calcification in the sheep model compared with the rat model. In conclusion, studies comparing degradation of vascular grafts in large and small animal models remain limited. For clinical translation of nanofiber vascular grafts, it is important to understand these differences.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Different degradation rates of nanofiber vascular grafts in small and large animal models

Fukunishi

Ong

Yesantharao

et al. 2020

J Tissue Eng Regen Med

View full text Add to dashboard Cite

show abstract

“…However, vascular tissue engineering was thought to be promising to produce regenerative tissue engineered vascular graft (TEVG) to meet the clinical demand . In the process of vascular tissue engineering, construction of functional vascular smooth muscle layer is the most important challenge since it provides the mechanical property and maintains integrity for the regenerative blood vessels …”

Section: Introductionmentioning

confidence: 99%

“…[1][2][3][4][5] In the process of vascular tissue engineering, construction of functional vascular smooth muscle layer is the most important challenge since it provides the mechanical property and maintains integrity for the regenerative blood vessels. [6][7][8][9][10][11] In order to successfully construct smooth muscle layer, smooth muscle cell's (SMC) penetration into the scaffold and its phenotype modulation within the scaffold are two prerequisites. The former confirms the cells can enter the scaffold to initiate the regeneration, and the latter ensured the cells could play the correct roles within the scaffold in the different periods to finalize regeneration and endow psychological functions.…”

Section: Introductionmentioning

confidence: 99%

The penetration and phenotype modulation of smooth muscle cells on surface heparin modified poly(ɛ‐caprolactone) vascular scaffold

Cao

Geng

Wen

et al. 2017

J Biomedical Materials Res

View full text Add to dashboard Cite

The tubular porous poly(ɛ-caprolactone) (PCL) scaffold was fabricated by electrospinning. After then, the scaffold's surface was firstly eroded by hexyldiamine to endow amine group, and heparin was covalently grafted to the surface to get surface heparin modified scaffold (ShPCL scaffold). It was found that ShPCL scaffold can induce smooth muscle cells (SMCs) to penetrate the scaffold surface, while the SMCs cannot penetrate the surface of PCL scaffold. Subsequently, the rabbit SMCs were seeded on the ShPCL scaffold and cultured for 14 days. It was found the expression of α-smooth muscle actin in ShPCL scaffold maintained much higher level than that in culture plate, which implied the SMC differentiation in ShPCL scaffold. Furthermore, the immunefluorescence staining of the cross-sections of ShPCL scaffold exhibited the expression of calponin in ShPCL scaffold can be detected after 7 and 14 days, whereas the expression of smooth muscle myosin heavy chain can also be detected at 14 days. These results proved that penetrated SMCs preferably differentiated in to contractile phenotype. The successful SMC penetration and the contractile phenotype expression implied ShPCL scaffold is a suitable candidate for regenerating smooth muscle layer in vascular tissue engineering. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 105A: 2806-2815, 2017.

show abstract

“…The vast majority of CVD-related deaths (>85%) are due to atherosclerosis [1] leading to ischemic stroke, ischemic heart disease, and peripheral artery disease [3]. Blood vessel replacement and bypass surgery are widely established as appropriate options for the treatment of severe atherosclerosis [4]. Both of them require a vascular conduit; i.e., an autologous great saphenous vein, radial artery, or internal mammary artery [5].…”

Section: Introductionmentioning

confidence: 99%

Conjugation with RGD Peptides and Incorporation of Vascular Endothelial Growth Factor Are Equally Efficient for Biofunctionalization of Tissue-Engineered Vascular Grafts

Антонова

Seifalian

Kutikhin

et al. 2016

IJMS

View full text Add to dashboard Cite

The blend of poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) and poly(ε-caprolactone) (PCL) has recently been considered promising for vascular tissue engineering. However, it was shown that PHBV/PCL grafts require biofunctionalization to achieve high primary patency rate. Here we compared immobilization of arginine–glycine–aspartic acid (RGD)-containing peptides and the incorporation of vascular endothelial growth factor (VEGF) as two widely established biofunctionalization approaches. Electrospun PHBV/PCL small-diameter grafts with either RGD peptides or VEGF, as well as unmodified grafts were implanted into rat abdominal aortas for 1, 3, 6, and 12 months following histological and immunofluorescence assessment. We detected CD31+/CD34+/vWF+ cells 1 and 3 months postimplantation at the luminal surface of PHBV/PCL/RGD and PHBV/PCL/VEGF, but not in unmodified grafts, with the further observation of CD31+CD34−vWF+ phenotype. These cells were considered as endothelial and produced a collagen-positive layer resembling a basement membrane. Detection of CD31+/CD34+ cells at the early stages with subsequent loss of CD34 indicated cell adhesion from the bloodstream. Therefore, either conjugation with RGD peptides or the incorporation of VEGF promoted the formation of a functional endothelial cell layer. Furthermore, both modifications increased primary patency rate three-fold. In conclusion, both of these biofunctionalization approaches can be considered as equally efficient for the modification of tissue-engineered vascular grafts.

show abstract

Tissue engineered vascular grafts: Origins, development, and current strategies for clinical application

Cited by 81 publications

References 60 publications

Different degradation rates of nanofiber vascular grafts in small and large animal models

Different degradation rates of nanofiber vascular grafts in small and large animal models

The penetration and phenotype modulation of smooth muscle cells on surface heparin modified poly(ɛ‐caprolactone) vascular scaffold

Conjugation with RGD Peptides and Incorporation of Vascular Endothelial Growth Factor Are Equally Efficient for Biofunctionalization of Tissue-Engineered Vascular Grafts

Contact Info

Product

Resources

About